Biocryst Pharmaceuticals Inc.
BCRX
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
22.6% downsideOvervalued by 22.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.09 Billion |
|---|---|
| Enterprise Value | $1.95 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.26 |
| Beta | 0.57 |
| Outstanding Shares | 242,258,000 |
Return
| Return on Equity | 82.69% |
|---|---|
| Return on Assets | -98.48% |
| Return on Invested Capital | -174.20% |
Valuation & Multiples
| P/E Ratio | -5.75 |
|---|---|
| PEG | 0 |
| Price to Sales | 3.28 |
| Price to Book Ratio | -3.28 |
| Enterprise Value to Revenue | 2.2 |
| Enterprise Value to EBIT | -4.15 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | -0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4522▼ 27.13% |
|---|---|
| Total Calls | 1,199,321▼ 1.00% |
| Total Puts | 542,313▼ 38.12% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 118.05%▲ 16.93% |
|---|---|
| Total Invested | $2.37B▲ 43.05% |
| Investors Holding | 315▲ 23.00% |
ESG Score
No data
About Biocryst Pharmaceuticals Inc.
CEO: Jon Stonehouse Relevant Senate Committees
Controls taxation, which directly affects corporate profitability, and influences healthcare spending (e.g., Medicare pricing), which is a major revenue driver for pharmaceutical companies.
Allocates federal spending, directly impacting funding for agencies like NIH (research) and FDA (regulation), as well as potential government procurement or R&D grants for biopharmaceutical companies.
Directly regulates the FDA (drug approval) and NIH (R&D funding), both of which are absolutely critical to the core business and success of a biological product manufacturer.
Has direct oversight over intellectual property (patents), which is fundamental to a pharmaceutical company's business model and valuation, and antitrust enforcement.